Chimerix, Inc. (NASDAQ:CMRX – Get Rating) – Capital One Financial issued their Q3 2022 earnings estimates for shares of Chimerix in a report released on Wednesday, September 7th. Capital One Financial analyst N. Quibria expects that the biopharmaceutical company will earn ($0.26) per share for the quarter. Capital One Financial currently has a “Overweight” rating and a $7.00 target price on the stock. The consensus estimate for Chimerix’s current full-year earnings is $1.86 per share. Capital One Financial also issued estimates for Chimerix’s Q4 2022 earnings at $2.44 EPS, FY2022 earnings at $2.00 EPS, Q1 2023 earnings at ($0.30) EPS, Q2 2023 earnings at ($0.32) EPS, Q3 2023 earnings at ($0.31) EPS, Q4 2023 earnings at ($0.02) EPS, FY2023 earnings at ($0.95) EPS, FY2024 earnings at ($0.92) EPS, FY2025 earnings at ($0.91) EPS and FY2026 earnings at ($0.74) EPS.
Chimerix (NASDAQ:CMRX – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Chimerix had a negative net margin of 17,482.40% and a negative return on equity of 171.05%. The business had revenue of $0.44 million during the quarter.
Chimerix Price Performance
Shares of Chimerix stock opened at $2.38 on Friday. Chimerix has a 52-week low of $1.27 and a 52-week high of $7.42. The stock has a market capitalization of $208.54 million, a price-to-earnings ratio of -1.97 and a beta of 1.15. The company has a fifty day moving average of $2.31 and a 200-day moving average of $3.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.00 and a current ratio of 2.18.
Institutional Investors Weigh In On Chimerix
Institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in shares of Chimerix in the 2nd quarter worth about $30,000. Principal Financial Group Inc. lifted its position in shares of Chimerix by 77.1% in the 2nd quarter. Principal Financial Group Inc. now owns 20,007 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 8,710 shares during the period. Walleye Trading LLC purchased a new stake in shares of Chimerix in the 2nd quarter worth about $45,000. Engineers Gate Manager LP purchased a new stake in shares of Chimerix in the 1st quarter worth about $54,000. Finally, E Fund Management Co. Ltd. purchased a new stake in shares of Chimerix in the 1st quarter worth about $59,000. 63.43% of the stock is owned by hedge funds and other institutional investors.
Chimerix Company Profile
Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.
- Get a free copy of the StockNews.com research report on Chimerix (CMRX)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- When Will the Hangover Finally Be Over for Seagate Technology?
- Are These Green Energy Companies Right For Your Portfolio?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.